Can a woman with lupus who is planning pregnancy continue hydroxychloroquine (Plaquenil), and what dose and monitoring are recommended?

Hydroxychloroquine in Women with Lupus Planning Pregnancy

Women with lupus planning pregnancy should absolutely continue hydroxychloroquine if already taking it, or start it if not already prescribed, at doses of 200-400 mg daily (≤5 mg/kg/day actual body weight), as this medication is strongly recommended throughout pregnancy to prevent disease flares and reduce adverse pregnancy outcomes. 1, 2, 3

Pre-Pregnancy Optimization

Continue or initiate hydroxychloroquine before conception as the cornerstone of lupus management in pregnancy planning. 1, 2, 3

• The American College of Rheumatology provides a strong recommendation to continue hydroxychloroquine during pregnancy if already taking it, and a conditional recommendation to start it if not already prescribed (unless contraindicated by allergy or intolerance). 1, 3
• Discontinuing hydroxychloroquine when planning pregnancy is a critical error that precipitates disease flares and increases maternal morbidity without providing any fetal benefit. 1, 3
• Hydroxychloroquine reduces lupus flares during pregnancy, decreases rates of preterm birth and intrauterine growth retardation, and may reduce preeclampsia risk when combined with low-dose aspirin. 1, 3

Dosing Recommendations

Prescribe hydroxychloroquine at ≤5 mg/kg/day based on actual body weight, with typical doses of 200-400 mg daily. 1, 4

• The recommended dose balances therapeutic benefit against retinopathy risk, which increases significantly above 5 mg/kg/day. 1
• For lupus erythematosus specifically, the FDA-approved dosage is 200-400 mg daily, administered as a single daily dose or in two divided doses. 4
• Doses above 400 mg daily are not recommended due to increased retinopathy risk. 4

Essential Pre-Pregnancy Assessments

Complete comprehensive laboratory testing before or early in pregnancy to stratify risk and guide monitoring. 2

• Test once for antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-β2GPI antibodies) to determine need for anticoagulation during pregnancy. 5, 2
• Test once for anti-Ro/SSA and anti-La/SSB antibodies to assess risk of neonatal lupus and congenital heart block. 2
• Obtain baseline complete blood count, urinalysis with protein:creatinine ratio, serum creatinine, complement levels (C3/C4), and anti-dsDNA antibody titers. 2

Ophthalmologic Screening

Obtain baseline ophthalmologic examination within the first year of starting hydroxychloroquine, though this is no longer required before initiating treatment. 1

• For patients without risk factors, annual ophthalmologic screening should begin after 5 years of therapy. 1
• For patients with risk factors (renal impairment with eGFR <60 ml/min/1.73 m², high doses, concomitant tamoxifen), initiate annual screening after 1 year rather than 5 years. 1
• Retinopathy risk is dose-dependent and cumulative, affecting 0.5% after 6 years and >20% after 20 years of treatment. 1

Additional Pregnancy-Specific Interventions

Add low-dose aspirin (81-100 mg daily) starting before 16 weeks of gestation and continue until delivery. 1, 2, 3

• This combination of hydroxychloroquine plus aspirin reduces preeclampsia risk in women with systemic lupus erythematosus. 1, 3
• Both the American College of Rheumatology and American College of Obstetricians and Gynecologists recommend aspirin prophylaxis for SLE patients due to high preeclampsia risk. 2

Implement antiphospholipid antibody-stratified treatment if testing is positive. 2

• Obstetric APS: low-dose aspirin plus prophylactic heparin. 2
• Thrombotic APS: low-dose aspirin plus therapeutic-dose heparin. 2

Pregnancy Monitoring Protocol

Monitor disease activity at least once per trimester with clinical assessment and laboratory testing. 2

• Each trimester assessment should include: complete blood count with differential, urinalysis with protein:creatinine ratio, serum C3/C4 complement levels, and anti-dsDNA antibody titers. 2
• Increase monitoring frequency based on individual disease activity and medication requirements. 2

Implement specialized fetal surveillance based on antibody status. 2

• For anti-Ro/SSA or anti-La/SSB positive patients: serial fetal echocardiography from weeks 16-26. 2
• If history of neonatal lupus in prior pregnancy: weekly fetal echocardiography. 2
• Routine ultrasonographic screening: first trimester (11-14 weeks), second trimester with Doppler (20-24 weeks), and third trimester monthly surveillance with Doppler studies. 2

Critical Contraindications

Do not prescribe hydroxychloroquine if the patient has:

• Known allergy to hydroxychloroquine or chloroquine (absolute contraindication). 1, 3, 4
• Severe adverse effects or intolerance to hydroxychloroquine. 3
• G6PD deficiency requires careful risk-benefit assessment, particularly in men of African, Asian, or Middle Eastern origin, though recent data suggest lower hemolysis risk than previously thought. 1, 3

Disease Activity Requirements

Achieve remission or low disease activity for several months on pregnancy-compatible medications before conception. 6

• Active disease at conception, especially active nephritis, is a major risk factor for adverse maternal and fetal outcomes. 5
• Patients with active lupus nephritis should avoid pregnancy while disease is active and for at least 6 months after disease becomes inactive. 3
• Blood pressure monitoring and limiting glucocorticoid exposure are essential measures during preconception planning. 5

Adherence Considerations

Emphasize medication adherence, as non-adherence has more pronounced effects on hydroxychloroquine exposure than physiological pregnancy changes. 7

• Hydroxychloroquine concentrations ≤100 ng/mL are suggestive of non-adherence regardless of trimester and are associated with significantly higher rates of preterm birth (OR 11.2). 7
• Take hydroxychloroquine with a meal or glass of milk to improve tolerability and adherence. 4

Breastfeeding Compatibility

Hydroxychloroquine is safe during breastfeeding with limited transfer into breast milk. 1, 3